These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19664754)

  • 1. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
    Sen HN; Levy-Clarke G; Faia LJ; Li Z; Yeh S; Barron KS; Ryan JG; Hammel K; Nussenblatt RB
    Am J Ophthalmol; 2009 Nov; 148(5):696-703.e1. PubMed ID: 19664754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
    Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
    J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.
    Kenawy N; Cleary G; Mewar D; Beare N; Chandna A; Pearce I
    Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):297-300. PubMed ID: 20922440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous daclizumab for recalcitrant ocular inflammatory disease.
    Bhat P; Castañeda-Cervantes RA; Doctor PP; Foster CS
    Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):687-92. PubMed ID: 19198869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
    Nussenblatt RB; Fortin E; Schiffman R; Rizzo L; Smith J; Van Veldhuisen P; Sran P; Yaffe A; Goldman CK; Waldmann TA; Whitcup SM
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7462-6. PubMed ID: 10377437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
    Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
    J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for juvenile idiopathic arthritis-associated uveitis.
    Magli A; Forte R; Navarro P; Russo G; Orlando F; Latanza L; Alessio M
    Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1601-6. PubMed ID: 23446556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial.
    Sen HN; Larson TA; Meleth AD; Smith WM; Nussenblatt RB
    Am J Ophthalmol; 2012 Jun; 153(6):1038-42. PubMed ID: 22465364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
    Quartier P; Baptiste A; Despert V; Allain-Launay E; Koné-Paut I; Belot A; Kodjikian L; Monnet D; Weber M; Elie C; Bodaghi B;
    Ann Rheum Dis; 2018 Jul; 77(7):1003-1011. PubMed ID: 29275333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing juvenile idiopathic arthritis-associated uveitis.
    Hawkins MJ; Dick AD; Lee RJ; Ramanan AV; Carreño E; Guly CM; Ross AH
    Surv Ophthalmol; 2016; 61(2):197-210. PubMed ID: 26599495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.
    Wroblewski K; Sen HN; Yeh S; Faia L; Li Z; Sran P; Gangaputra S; Vitale S; Sherry P; Nussenblatt R
    Can J Ophthalmol; 2011 Aug; 46(4):322-8. PubMed ID: 21816251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.
    Gregory AC; Kempen JH; Daniel E; Kaçmaz RO; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE;
    Ophthalmology; 2013 Jan; 120(1):186-92. PubMed ID: 23062650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
    Tynjälä P; Kotaniemi K; Lindahl P; Latva K; Aalto K; Honkanen V; Lahdenne P
    Rheumatology (Oxford); 2008 Mar; 47(3):339-44. PubMed ID: 18238789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
    Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
    Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
    Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
    Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.